Hematopathology — MCQs

A 63-year-old man presented with massive splenomegaly, lymphadenopathy, and a total leukocyte count of 17,000 per mm³. Flow cytometry showed CD23-negative and CD5-positive monoclonal B-cells with bright kappa positivity, comprising 80% of the peripheral blood lymphoid cells. What is the most likely diagnosis?

Q980Easy

Basophilic stippling is seen in which of the following cells?

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 971: Which of the following conditions is characterized by a "punched-out" appearance in the skull?

A. Multiple myeloma (Correct Answer)
B. Thalassemia
C. Carcinoma of the lung
D. Hyperparathyroidism

Explanation: **Explanation:** **Multiple Myeloma (Correct Answer):** Multiple myeloma is a plasma cell dyscrasia characterized by the neoplastic proliferation of a single clone of plasma cells [5]. These cells secrete osteoclast-activating factors (such as **RANK-L** and **IL-6**), which stimulate osteoclasts and inhibit osteoblasts. This leads to purely lytic bone lesions without any reactive new bone formation. On a skull X-ray, these appear as sharply demarcated, circular, "punched-out" radiolucent lesions [1]. **Analysis of Incorrect Options:** * **Thalassemia:** Characterized by ineffective erythropoiesis and massive marrow expansion. This results in a **"Hair-on-end"** or "Crew-cut" appearance on the skull X-ray due to vertical striations of new bone, rather than lytic holes. * **Carcinoma of the Lung:** While lung cancer can metastasize to the bone, these lesions are often irregular and may be osteoblastic (sclerotic) or mixed. They do not typically present with the classic, uniform "punched-out" morphology seen in myeloma. * **Hyperparathyroidism:** Excess PTH leads to increased osteoclast activity, but the classic skull finding is a diffuse, granular demineralization known as a **"Salt and pepper"** appearance. It may also present with localized "Brown tumors." **High-Yield Clinical Pearls for NEET-PG:** * **CRAB Criteria:** **C**alcium (High), **R**enal failure, **Anemia**, **B**one lesions [1]. * **M-Spike:** Found on Serum Protein Electrophoresis (usually IgG) [2]. * **Bence-Jones Proteins:** Light chains found in urine (not detected by standard dipstick) [4]. * **Blood Smear:** Characterized by **Rouleaux formation** due to increased globulins [4]. * **Bone Scan:** Often **negative** in Multiple Myeloma because there is no osteoblastic activity; X-rays or MRI are preferred [3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 608. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 616-617. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 617-618. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 607-608. [5] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 606-607.

Question 972: Neoplastic cells with multilobulated nuclei ('clover leaf' or flower cells) are seen in which of the following?

A. Diffuse large B cell lymphoma (DLBCL)
B. Adult T-cell leukemia (ATLL) (Correct Answer)
C. Anaplastic large cell lymphoma (ALCL)
D. Mycosis fungoides

Explanation: ### Explanation **Correct Answer: B. Adult T-cell leukemia (ATLL)** **Why it is correct:** Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm caused by the **Human T-cell Lymphotropic Virus type 1 (HTLV-1)**. The hallmark morphological feature of this disease is the presence of neoplastic CD4+ T-cells in the peripheral blood that exhibit highly irregular, **multilobulated nuclei**. These are classically described as **'clover-leaf' cells** or **'flower cells'**. This characteristic appearance is due to deep nuclear indentations and is a high-yield diagnostic clue for NEET-PG. **Why the other options are incorrect:** * **A. DLBCL:** These cells typically show large nuclei with prominent nucleoli and a high nucleocytoplasmic ratio, but they do not form the characteristic "flower" shape [3]. * **C. ALCL:** This is characterized by **'Hallmark cells'** which have kidney-shaped or horseshoe-shaped nuclei and are typically ALK-positive [1]. * **D. Mycosis fungoides:** The neoplastic T-cells here exhibit **'cerebriform nuclei'** (resembling the folds of the brain) rather than the distinct petals of a flower cell [1],[2]. **High-Yield Clinical Pearls for NEET-PG:** * **Association:** Strongly linked to **HTLV-1** infection (endemic in Japan, the Caribbean, and parts of Africa). * **Clinical Presentation:** Patients often present with generalized lymphadenopathy, hepatosplenomegaly, skin lesions, and **lytic bone lesions** with **hypercalcemia** (often confused with Multiple Myeloma, but ATLL presents with a skin rash). * **Immunophenotype:** Typically **CD4+** and **CD25+** (the alpha chain of the IL-2 receptor). * **Prognosis:** The acute form is highly aggressive with a poor prognosis. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 613-614. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 564-565. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 563-564.

Question 973: The t(9;22)(q34;q11) translocation is commonly associated with which of the following conditions?

A. Acute Myeloid Leukemia (AML)
B. Acute Lymphoblastic Leukemia (ALL)
C. Chronic Myeloid Leukemia (CML) (Correct Answer)
D. Chronic Lymphocytic Leukemia (CLL)

Explanation: ### Explanation **Correct Option: C. Chronic Myeloid Leukemia (CML)** The **t(9;22)(q34;q11)** translocation is the hallmark of Chronic Myeloid Leukemia (CML), present in >95% of cases [1], [2]. This translocation results in the **Philadelphia chromosome (Ph)**. At the molecular level, the *ABL1* proto-oncogene on chromosome 9 is transposed to the *BCR* (breakpoint cluster region) on chromosome 22 [3]. This creates a **BCR-ABL1 fusion gene**, which encodes a chimeric protein with constitutive **tyrosine kinase activity** [1], [3]. This protein drives uncontrolled proliferation of the myeloid lineage by activating downstream signaling pathways like RAS and STAT. **Analysis of Incorrect Options:** * **A. Acute Myeloid Leukemia (AML):** While t(9;22) can rarely occur in AML (de novo), it is not the characteristic marker. AML is more typically associated with t(8;21), t(15;17) in APML, or inv(16). * **B. Acute Lymphoblastic Leukemia (ALL):** The Philadelphia chromosome is found in ~25-30% of adult ALL and ~3-5% of pediatric ALL. While significant, it is not the *defining* or most common association compared to CML. In ALL, it signifies a poor prognosis. * **D. Chronic Lymphocytic Leukemia (CLL):** CLL is characterized by deletions (13q, 11q, 17p) or trisomy 12, rather than the t(9;22) translocation. **NEET-PG High-Yield Pearls:** * **Molecular Weight:** In CML, the fusion protein is typically **p210**; in Ph+ ALL, it is often **p190**. * **Diagnosis:** FISH or RT-PCR is used to detect the BCR-ABL1 rearrangement. * **Treatment:** **Imatinib** (a tyrosine kinase inhibitor) is the first-line targeted therapy that revolutionized CML management. * **LAP Score:** Leukocyte Alkaline Phosphatase (LAP) score is characteristically **decreased** in CML, helping differentiate it from a Leukemoid reaction (where LAP is increased). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 624. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 225-226. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 624-625.

Question 974: Which of the following is NOT typically seen in Hemophilia A?

A. Decreased Factor VIII
B. Prolonged PTT
C. Prolonged PT (Correct Answer)
D. Normal Bleeding Time

Explanation: **Explanation:** Hemophilia A is an X-linked recessive bleeding disorder caused by a deficiency or dysfunction of **Factor VIII** [2], [3]. To answer this question, one must understand the components of the coagulation cascade and how they are measured in the laboratory [1]. **Why "Prolonged PT" is the correct answer:** The **Prothrombin Time (PT)** measures the **Extrinsic** and **Common pathways** (Factors VII, X, V, II, and I) [1]. Since Factor VIII is a component of the **Intrinsic pathway**, its deficiency does not affect the PT. Therefore, a prolonged PT is NOT seen in Hemophilia A; the PT remains characteristically **normal**. **Analysis of Incorrect Options:** * **Decreased Factor VIII:** This is the primary molecular defect in Hemophilia A [2]. * **Prolonged PTT:** The **Activated Partial Thromboplastin Time (aPTT)** measures the **Intrinsic** and **Common pathways** (Factors XII, XI, IX, VIII, X, V, II, and I) [1]. A deficiency in Factor VIII leads to a characteristically prolonged PTT. * **Normal Bleeding Time:** Bleeding time is a measure of **primary hemostasis** (platelet function and vessel wall integrity). Since Hemophilia A is a disorder of secondary hemostasis (coagulation factors) [3], the platelet count and bleeding time are typically normal. **NEET-PG High-Yield Pearls:** * **Mixing Study:** If a patient has a prolonged PTT, a mixing study is performed. If the PTT corrects, it indicates a factor deficiency (like Hemophilia); if it fails to correct, it suggests an inhibitor. * **Clinical Presentation:** Hemophilia typically presents with deep tissue bleeding, **hemarthrosis** (bleeding into joints), and delayed postsurgical bleeding. * **Treatment:** Recombinant Factor VIII or **Emicizumab** (a bispecific antibody that mimics Factor VIII by bridging IXa and X). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 128-130. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 670-671. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 622-623.

Question 975: All are important laboratory features of hemolytic anemia, EXCEPT:

A. Normal AST (Correct Answer)
B. Elevated urobilinogen in stool
C. Reduced haptoglobin
D. Macrocytes in blood smear

Explanation: **Explanation:** Hemolytic anemia is characterized by the premature destruction of red blood cells (RBCs). To identify the correct answer, one must understand the biochemical and morphological consequences of RBC lysis. **Why "Normal AST" is the correct answer:** Aspartate aminotransferase (AST) is not only found in the liver but is also present in high concentrations within RBCs. When hemolysis occurs, AST is released into the plasma. Therefore, **elevated AST** (not normal) is a characteristic feature of hemolytic anemia. Note that ALT remains relatively normal as it is more specific to hepatocytes. **Analysis of Incorrect Options:** * **Elevated urobilinogen in stool:** Increased RBC breakdown leads to high levels of unconjugated bilirubin. This is processed by the liver and excreted into the gut, where bacteria convert it to stercobilinogen (stool urobilinogen). Hence, fecal urobilinogen is increased [1]. * **Reduced haptoglobin:** Haptoglobin is a plasma protein that binds free hemoglobin. In intravascular hemolysis, haptoglobin levels drop significantly (often to near zero) as it is consumed while clearing released hemoglobin [1]. * **Macrocytes in blood smear:** Hemolysis triggers the bone marrow to compensate by releasing young RBCs (reticulocytes). Reticulocytes are larger than mature RBCs (MCV >100 fL), leading to a "polychromatic" macrocytosis on a peripheral smear [1]. **NEET-PG High-Yield Pearls:** 1. **Best initial test for hemolysis:** Reticulocyte count (shows erythroid hyperplasia) [2]. 2. **Most specific marker for intravascular hemolysis:** Low serum haptoglobin [1]. 3. **LDH:** Markedly elevated in hemolysis (specifically LDH-1 and LDH-2). 4. **Urine findings:** Hemoglobinuria and hemosiderinuria are seen in intravascular hemolysis, but **bilirubinuria is absent** (acholuric jaundice) because unconjugated bilirubin is water-insoluble [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 639-640. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 597-598.

Question 976: Duffy antigen is associated with which Cluster of Differentiation?

A. CD123
B. CD234 (Correct Answer)
C. CD345
D. CD456

Explanation: The **Duffy antigen**, also known as the Duffy Antigen Receptor for Chemokines (DARC), is a glycoprotein expressed on the surface of red blood cells (RBCs) and endothelial cells. In the Cluster of Differentiation (CD) nomenclature, it is designated as **CD234**. **1. Why CD234 is Correct:** CD234 acts as a multi-ligand receptor for various chemokines. Its primary clinical significance in hematopathology lies in its role as the portal of entry for **Plasmodium vivax** merozoites [1]. Individuals who are "Duffy-negative" (Fy a-b-) lack this receptor on their RBCs, providing them with natural resistance against *P. vivax* malaria. This phenotype is highly prevalent in West African populations. **2. Analysis of Incorrect Options:** * **CD123:** This is the **IL-3 receptor alpha chain**. It is a high-yield marker for **Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)** and is also expressed in Hairy Cell Leukemia. * **CD345 and CD456:** These are **distractor options**. The current CD nomenclature officially extends to approximately CD371. Numbers in the 300s and 400s are either recently assigned or do not exist in standard medical curricula, making them common "filler" options in competitive exams. **Clinical Pearls for NEET-PG:** * **Malaria Link:** Duffy-negative status protects against *P. vivax* but **not** *P. falciparum* [1]. * **Chemokine Sink:** CD234 on endothelial cells acts as a "sink" to clear inflammatory chemokines from circulation. * **Genetics:** The Duffy gene is located on **Chromosome 1**. * **Transfusion Medicine:** Anti-Fya and Anti-Fyb antibodies are clinically significant and can cause Delayed Hemolytic Transfusion Reactions (DHTR). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Infectious Diseases, pp. 398-400.

Question 977: Which of the following is a low-grade non-Hodgkin lymphoma?

A. Follicular (Correct Answer)
B. Large cell
C. Diffuse large cell
D. Lymphoblastic

Explanation: **Explanation:** Non-Hodgkin Lymphomas (NHL) are traditionally classified based on their clinical behavior into **Indolent (Low-grade)** and **Aggressive (High-grade)** types. **Why Follicular Lymphoma is correct:** Follicular Lymphoma is the most common indolent (low-grade) NHL. It arises from germinal center B-cells and is characterized by a slow, protracted clinical course [1]. It is cytogenetically defined by the **t(14;18)** translocation, which leads to the overexpression of the **BCL-2** anti-apoptotic protein, preventing programmed cell death in B-cells [1], [2]. **Analysis of Incorrect Options:** * **Large cell & Diffuse large cell (DLBCL):** These are synonymous in this context. DLBCL is the most common NHL overall and is classified as a **high-grade (aggressive)** lymphoma [3]. While potentially curable with intensive chemotherapy (R-CHOP), it is rapidly fatal if left untreated. * **Lymphoblastic Lymphoma:** This is a **very high-grade (highly aggressive)** precursor T-cell or B-cell neoplasm, closely related to Acute Lymphoblastic Leukemia (ALL). It typically affects children and adolescents and requires urgent, intensive treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Grading vs. Staging:** Low-grade lymphomas (like Follicular) are often disseminated at diagnosis (Stage III/IV) but have a long survival, whereas high-grade lymphomas are more likely to be localized but require immediate systemic therapy [3]. * **Transformation:** Follicular lymphoma has a risk of "transformation" into a more aggressive high-grade lymphoma (Richter’s-like transformation), usually DLBCL. * **Immunophenotype:** Follicular lymphoma is typically **CD10+, BCL-2+, and BCL-6+**. BCL-2 positivity helps differentiate follicular lymphoma from reactive follicular hyperplasia (which is BCL-2 negative). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 561-562. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 563-564.

Question 978: Which chromosomal translocation is characteristic of Chronic Myeloid Leukemia (CML)?

A. t(2;08)
B. t(8;14)
C. t(9;22) (Correct Answer)
D. t(15;17)

Explanation: **Explanation:** **Correct Answer: C. t(9;22)** Chronic Myeloid Leukemia (CML) is defined by the presence of the **Philadelphia chromosome (Ph)**, which results from a reciprocal translocation between chromosomes 9 and 22 [1]. This translocation fuses the **ABL1** proto-oncogene (ch 9) with the **BCR** gene (ch 22), creating the **BCR-ABL1 fusion gene** [2]. This hybrid gene encodes a constitutively active **tyrosine kinase**, which drives uncontrolled myeloid proliferation and inhibits apoptosis [3]. **Analysis of Incorrect Options:** * **A. t(2;8):** This is a variant translocation associated with **Burkitt Lymphoma** (involving the *MYC* gene and the *kappa* light chain locus). * **B. t(8;14):** This is the classic translocation seen in **Burkitt Lymphoma**, where the *MYC* oncogene on chromosome 8 is moved to the Ig heavy chain locus on chromosome 14, leading to MYC overexpression. * **D. t(15;17):** This is the hallmark of **Acute Promyelocytic Leukemia (APL - AML M3)** [3]. It involves the *PML-RARA* fusion, which makes the disease uniquely responsive to All-Trans Retinoic Acid (ATRA). **High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** The gold standard for CML diagnosis is demonstrating the t(9;22) via Cytogenetics (Karyotyping) or FISH, or the BCR-ABL1 transcript via RT-PCR. * **Treatment:** **Imatinib** (a Tyrosine Kinase Inhibitor) is the first-line targeted therapy [4]. * **Laboratory Findings:** Characterized by a "leukemoid-like" blood picture but with a **low Leukocyte Alkaline Phosphatase (LAP) score** (unlike a true leukemoid reaction where LAP is high). * **Progression:** If untreated, CML can progress from the Chronic Phase to an Accelerated Phase and finally a **Blast Crisis** (which can be either Myeloid or Lymphoid) [4]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 225-226. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 624. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 605-607. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 611-612.

Question 979: A 63-year-old man presented with massive splenomegaly, lymphadenopathy, and a total leukocyte count of 17,000 per mm³. Flow cytometry showed CD23-negative and CD5-positive monoclonal B-cells with bright kappa positivity, comprising 80% of the peripheral blood lymphoid cells. What is the most likely diagnosis?

A. Mantle cell lymphoma (Correct Answer)
B. Splenic lymphoma with villous lymphocytes
C. Follicular lymphoma
D. Hairy cell leukemia

Explanation: ### Explanation The diagnosis is **Mantle Cell Lymphoma (MCL)**. This case highlights the classic immunophenotypic "signature" used to differentiate small B-cell lymphomas in clinical practice. **Why Mantle Cell Lymphoma is Correct:** MCL typically presents in older males with generalized lymphadenopathy, splenomegaly, and a leukemic phase (elevated WBC) [1]. The key to this question lies in the **Flow Cytometry**: * **CD5 Positive:** Narrows the differential to MCL and Chronic Lymphocytic Leukemia (CLL) [1]. * **CD23 Negative:** This is the crucial differentiator; CLL is characteristically CD23 positive, while MCL is CD23 negative. * **Bright Surface Immunoglobulin (Kappa):** MCL expresses intense (bright) surface Ig, whereas CLL expresses weak/dim surface Ig [1]. **Why Other Options are Incorrect:** * **B. Splenic Lymphoma with Villous Lymphocytes (SLVL):** While it presents with massive splenomegaly, it is typically **CD5 negative**. * **C. Follicular Lymphoma:** These cells are typically **CD5 negative** and CD10 positive [3]. They also lack the massive splenomegaly seen in MCL. * **D. Hairy Cell Leukemia:** Characterized by massive splenomegaly and pancytopenia (not leukocytosis). Immunophenotype shows **CD11c, CD25, and CD103 positivity**; it is CD5 negative. **NEET-PG High-Yield Pearls:** * **Cytogenetics:** MCL is associated with **t(11;14)**, leading to overexpression of **Cyclin D1** (PRAD-1 gene) [1]. * **Morphology:** Look for "pink" histiocytes and a vague nodular growth pattern in lymph nodes [2]. * **Gastrointestinal Involvement:** MCL can present as **Lymphomatous Polyposis** (multiple polyps in the GI tract). * **Marker Summary:** MCL = CD5(+), CD23(–), Cyclin D1(+), FMC7(+). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 609-612. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 562-563. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 602-604.

Question 980: Basophilic stippling is seen in which of the following cells?

A. Eosinophils
B. RBCs (Correct Answer)
C. Basophils
D. Neutrophils

Explanation: **Explanation:** **Basophilic stippling** (also known as punctate basophilia) refers to the presence of numerous, fine or coarse blue-purple granules distributed throughout the cytoplasm of **Red Blood Cells (RBCs)** on a peripheral blood smear [1]. **Why RBCs is the correct answer:** The underlying mechanism involves the **pathological aggregation of ribosomes** (residual RNA). In normal reticulocytes, RNA is distributed uniformly; however, in certain disease states, these ribosomes clump together, becoming visible under light microscopy with Romanowsky stains (like Leishman or Giemsa). This is a hallmark finding in: * **Lead Poisoning:** Lead inhibits the enzyme *5'-nucleotidase*, preventing the degradation of ribosomal RNA [3]. * **Sideroblastic Anemia:** Often presents with coarse stippling. * **Thalassemia:** Specifically Beta-thalassemia trait [2]. **Why other options are incorrect:** * **Basophils:** While the name is similar, basophils are a type of WBC characterized by large, coarse, dark-purple granules that contain histamine and heparin, which obscure the nucleus [1]. They do not exhibit "stippling." * **Eosinophils & Neutrophils:** These are granulocytes. Eosinophils contain large orange-red acidophilic granules, and neutrophils contain fine pinkish-purple granules [1]. The term "stippling" is never used to describe their normal or toxic granulation. **High-Yield Clinical Pearls for NEET-PG:** 1. **Coarse vs. Fine:** Coarse stippling is highly suggestive of **Lead Poisoning** [3], whereas fine stippling is often seen in increased erythropoiesis (e.g., severe anemia). 2. **Mnemonic (TAILS):** Causes of microcytic anemia where stippling may be seen include **T**halassemia, **A**nemia of chronic disease, **I**ron deficiency (rarely), **L**ead poisoning, and **S**ideroblastic anemia. 3. **Distinction:** Do not confuse basophilic stippling with **Pappenheimer bodies** (iron inclusions) or **Howell-Jolly bodies** (DNA remnants) [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 578-579. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, p. 648. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Infectious Diseases, pp. 418-419.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free